Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin

Journal of Hepatology

Volumn 51, Issue 6, 2009, Pages 984-990

  Grasso, Alessandro ^a   Malfatti, Federica ^a   Leo, Pasqualina De ^a   Martines, Hugo ^a   Fabris, Paolo ^b   Toscanini, Federica ^a   Anselmo, Marco ^a   Menardo, Giorgio ^a  

^a San Paolo Hospital   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Chronic hepatitis C; Genotype 1; HOMA IR; Insulin resistance; Rapid virologic response

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; FIBROSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; STEATOSIS; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 71549129264     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.07.008     Document Type: Article

References (30)

1. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358 (2001) 958-965
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Hadziyannis S., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha-2a plus ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Int Med 40 (2004) 346-355
4. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
5. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales F.L.J., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40 kDa)/ribavirin. J Hepatol 43 (2005) 425-433
6. Jensen D.M., Morgan T.R., Marcellin P., Pockros P.J., Reddy K.R., Hadziyannis S.J., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kDa)/ribavirin therapy. Hepatology 43 (2006) 954-960
7. Yu J.W., Wang G.Q., Sun L.J., Li X.G., and Li S.C. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22 (2007) 832-836
8. Shiffman M.L., Chung R.T., and Hamzeh F.M. Time to HCV RNA undetectability supersedes baseline factors in predicting SVR in patients with HCV genotype 1. J Hepatol 48 Suppl. 2 (2008) S313
9. Mangia A., Minerva N., Bacca D., Cozzolongo R., Ricci G.L., Carreta V., et al. Individualized treatment duration for hepatitis C genotype 1 patients. A randomized controlled trial. Hepatology 47 (2008) 43-50
10. Ferenci P., Laferl H., Scherzer T.M., Gschwantler M., Maieron A., Brunner, et al. Peginterfeon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135 (2008) 451-458
11. Ishak K.G. Chronic hepatitis: morphology and nomenclature. Mod Pathol 7 (1994) 690-713
12. Matthew D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment. Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
13. Ikeda Y., Suehiro T., Nakamura T., Kumon Y., and Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 48 (2001) 81-86
14. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., Salmeron J., Diago M., Fernandez-Rodriguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
15. Payan C., Pivert A., Morand P., Fafi-Kremer S., Carrat F., Pol S., et al. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut 56 (2007) 1111-1116
16. Pearlman B., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 46 (2007) 1688-1694
17. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., et al. Peginterferon alpha-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 (2005) 2609-2617
18. Nasta P., Gatti F., Puoti M., Cologni G., Bergamaschi V., Borghi F., et al. Insulin resistance impairs rapid virological response in HIV/hepatitis C virus coinfected patients on peginterferon-alpha-2a. AIDS 22 (2008) 857-861
19. Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Ishibashi K., Matsuura Y., et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 (1997) 1527-1531
20. Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Tsukamoto K., Kimura S., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126 (2004) 840-848
21. Fartoux L., Poujol-Robert A., Guéchot J., Wendum D., Poupon R., and Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54 (2005) 1003-1008
22. Muzzi A., Leandro G., Rubbia-Brandt L., James R., Kaiser O., Malinverni R., et al. Insulin resistance is associated with fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 42 (2005) 41-46
23. Moucari R., Asselah T., Cazals-Hatem D., Voitot H., Boyer N., Ripault M.P., et al. Insulin resistance in chronic hepatitis C: association with genotype 1 and 4, serum HCV RNA, level, and liver fibrosis. Gastroenterology (2008) 134;416-423
24. Harrison S.A. Correlation between insulin resistance and hepatitis C viral load. Hepatology 43 (2006) 1168
25. Kawaguchi T., Ide T., Taniguchi E., Hirano E., Itou M., Sumie S., et al. Clearance of HCV improves insulin resistance, beta-cell function and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102 (2007) 570-576
26. Huang Y., Feld J.J., Sapp R.K., Nanda S., Lin J.H., Blatt K.M., et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132 (2007) 733-744
27. Persico M., Capasso M., Persico E., Svelto M., Russo R., Spano D., et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 46 (2007) 1009-1015
28. Tarantino G., Conca P., Ariello M., and Mastrolia M. Does a lower insulin resistance affect antiviral therapy response in patients suffering from HCV related chronic hepatitis?. Gut 55 (2006) 585-586
29. Romero-Gomez M., Diago M., Andrade R.J., Calleja J.L., Salmeron J., Fernández-Rodriguez C.M., et al. Metformin with peginterferon alfa-2a and ribavirin in the treatment of nai{dotless}̈ve genotype 1 chronic hepatitis C patients with insulin resistance (TRIC-1): final result of a randomised and double-blinded trial. Hepatology 48 (2008) 380A LB6
30. Overbeck K., Gennè D., Golay A., and Negro F. Swiss Association for the Study of the Liver (SASL) Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol 49 (2008) 295-298